Literature DB >> 15710287

Pathology in patients with ventricular assist devices: a study of 21 autopsies, 24 ventricular apical core biopsies and 24 explanted hearts.

Alan G Rose1, Soon J Park.   

Abstract

BACKGROUND: Ventricular assist devices (VADs) are used as a bridge to cardiac transplantation or as a permanent or sometimes temporary treatment for end stage heart failure.
METHODS: Our autopsy and surgical pathology experience with VADs prior to August 2002 was reviewed. Noted were patient's age, sex, underlying (UCOD) and proximate causes of death (PCOD), duration of VAD implantation, presence of native or prosthetic valvar disease and organ complications. Myocardium from biopsies and explanted hearts were blindly assessed for coagulative necrosis (CN), contraction bands (CB), myocytolysis (MC), increased eosinophilia (IE), myocyte waviness (MW) and fibrosis (F). Each was graded as either mild (score 1), moderate (score 2) or severe (score 3).
RESULTS: Autopsy patients: Twenty-one patients, with mean age 55 years (range 10-73), comprised 10 women and 11 men. UCOD was ischemic disease in 16 patients, dilated cardiomyopathy in 4 and aortic valve disease in 1. The mean duration of VAD implantation was 125.7 days (range 1-1095 days, S.D.=253.6). Five patients had biventricular VADs, and 16 had LVAD only. Acquired aortic valve fusion was noted in three patients. PCOD was VAD related in six, donor heart problem in four, cerebrovascular accident in four, miscellaneous in three, pulmonary hypertension in two and aortic disease in two patients. Morbidity: local liver necrosis in seven, acquired aortic valve disease in four, gut infarction in three, abdominal aortic aneurysm in two and host cell assault against VAD porcine aortic valves in one case. Biopsies and explanted hearts: Twenty-four patients had a mean age of 53 years (range 38-68, S.D.=8.6). VADs were implanted for 177.8 days (range 7-593 days, S.D.=151.1). Comparison of histologic scores of biopsies with explanted hearts showed the following: CN 1.33 (S.D.=1.4)/0.21 (S.D.=0.66; P<.001); CB: 2.1 (S.D.=0.93)/0.83 (S.D.=0.28; NS); MC: 0.88 (S.D.=1.19)/0.13 (S.D.=0.34; P<.01); IE: 1.71 (S.D.=1.27)/0.38 (S.D.=0.65; NS); fibrosis: 1.08 (S.D.=1.35)/1.75 (S.D.=1.26; NS); and MW: 1.50 (S.D.=1.22)/0.59 (S.D.=0.73; P<.01). Acquired aortic stenosis developed in six hearts, and one heart showed thrombotic occlusion of the left ventricular outflow tract below an aortic bioprosthesis.
CONCLUSIONS: VAD significantly reduced the amount of CN, MC and MW in the left ventricle but may lead to acquired aortic stenosis of native aortic valves or total occlusive thrombosis of aortic prosthetic valves. Proximate cause of death was, most often, VAD related.

Entities:  

Mesh:

Year:  2005        PMID: 15710287     DOI: 10.1016/j.carpath.2004.10.002

Source DB:  PubMed          Journal:  Cardiovasc Pathol        ISSN: 1054-8807            Impact factor:   2.185


  11 in total

1.  The future of adult cardiac assist devices: novel systems and mechanical circulatory support strategies.

Authors:  Carlo R Bartoli; Robert D Dowling
Journal:  Cardiol Clin       Date:  2011-11       Impact factor: 2.213

2.  In vivo evaluation of the HeartWare centrifugal ventricular assist device.

Authors:  Egemen Tuzun; Katy Roberts; William E Cohn; Murat Sargin; Courtney J Gemmato; Branislav Radovancevic; O H Frazier
Journal:  Tex Heart Inst J       Date:  2007

3.  Cellular, molecular, genomic changes occurring in the heart under mechanical circulatory support.

Authors:  Michele Gallo; Vincenzo Tarzia; Laura Iop; Jonida Bejko; Giacomo Bortolussi; Roberto Bianco; Tomaso Bottio; Gino Gerosa
Journal:  Ann Cardiothorac Surg       Date:  2014-09

4.  What you do not know, you do not recognize…and you do not improve future patient care…particularly in extracorporeal life support (ECLS) patients.

Authors:  Roberto Lorusso; Domenico Corradi
Journal:  J Thorac Dis       Date:  2019-09       Impact factor: 2.895

5.  Pathological findings in cardiac apex removed during implantation of left ventricular assist devices (LVAD) are non-specific: 13-year-experience at a German Heart Center.

Authors:  Thomas Strecker; Johannes Rösch; Michael Weyand; Abbas Agaimy
Journal:  Int J Clin Exp Pathol       Date:  2014-08-15

6.  Disseminated malignancy after extracorporeal life support and left ventricular assist device, diagnosed by left ventricular apical core biopsy.

Authors:  Tine E Philipsen; Tom Vermeulen; Viviane M Conraads; Inez E Rodrigus
Journal:  Interact Cardiovasc Thorac Surg       Date:  2013-07-30

Review 7.  Reverse remodeling with left ventricular assist devices: a review of clinical, cellular, and molecular effects.

Authors:  Amrut V Ambardekar; Peter M Buttrick
Journal:  Circ Heart Fail       Date:  2011-03       Impact factor: 8.790

8.  Incomplete recovery of myocyte contractile function despite improvement of myocardial architecture with left ventricular assist device support.

Authors:  Amrut V Ambardekar; John S Walker; Lori A Walker; Joseph C Cleveland; Brian D Lowes; Peter M Buttrick
Journal:  Circ Heart Fail       Date:  2011-05-03       Impact factor: 8.790

9.  Forensic Considerations in a Series of 14 Deaths of Patients with a Left Ventricular Assist Device.

Authors:  Peter T Lin; Sarah Thomas
Journal:  Acad Forensic Pathol       Date:  2020-01-31

10.  Theoretical estimation of cannulation methods for left ventricular assist device support as a bridge to recovery.

Authors:  Ki Moo Lim; Jeong Sang Lee; Jin-Ho Song; Chan-Hyun Youn; Jae-Sung Choi; Eun Bo Shim
Journal:  J Korean Med Sci       Date:  2011-11-29       Impact factor: 2.153

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.